Kenneth Moch

President & CEO

Mr. Moch joined Cognition Therapeutics in October 2016 as President & CEO. He has broad expertise building, financing and leading private and public life science companies from start-up through commercialization, having previously served as President & CEO of four life science companies: Chimerix, Inc., BioMedical Enterprises, Alteon, Inc., and Biocyte Corporation, where he pioneered the storage and therapeutic use of cord blood stem cells and launched the first cord blood stem cell storage bank.

Read More

Susan Catalano, PhD

Chief Scientific Officer and Founder

Dr. Catalano is the founder of Cognition Therapeutics and architect of its proprietary and unique biological discovery platform that is based on unbiased phenotypic screens in the target cell population of mature primary neurons. She is an expert in synaptic plasticity, Alzheimer’s disease and the biology of protein oligomers, the toxic shapes of protein that underlie many neurodegenerative diseases. Using her 14 years prior experience of Alzheimer’s drug discovery and high content screening technology she and her team have discovered a new Alzheimer’s target and novel candidate therapeutic leads, one of which is currently in clinical testing for therapy of Alzheimer’s disease.

Read More

Hank Safferstein, PhD, JD

Senior Vice President

Dr. Safferstein joined Cognition Therapeutics as CEO when the Company established operations in Pittsburgh in 2007. From then until October 2016 he served in this role and was responsible for raising several rounds of financing from Angel investors and other financial institutions enabling Cognition Therapeutics to progress its drug discovery and development efforts to the clinical stage. Prior to this, Dr. Safferstein served as Vice President, Business Development, Omrix Biopharmaceuticals, a commercial-stage biosurgical and passive immunotherapy company.

Read More

Gilbert M. Rishton, PhD

Chief Medicinal Chemistry Advisor

Dr. Rishton is a co-founder and the inventor of the proprietary conditioned extraction chemical library at Cognition Therapeutics. He has widespread pharma drug discovery experience and has led drug discovery programs across multiple therapeutic areas for over 20 years. He has leveraged this experience to develop medicinal chemistry scaffolds instrumental in identifying sigma-2/PGRMC1 as a pharmacologically attractive Alzheimer’s drug target.

Read More

Michael Grundman, MD, MPH

Chief Medical Advisor

Dr.Grundman has recently joined Cognition Therapeutics to provide leadership for their clinical strategy and product development. He has over 25 years’ experience in clinical research in CNS disorders. He is President and CEO of Global R&D Partners, LLC, a consulting firm that advises pharmaceutical and biotechnology companies on development of novel agents for the diagnosis and treatment of serious and life threatening diseases.

Read More

Stephen DiPalma, MBA

Chief Financial Officer

Mr. DiPalma is a Managing Director at Danforth Advisors, LLC, where he has served since April 2014. He brings more than 25 years of experience in providing life sciences and healthcare, which includes founding two start-ups, working with venture-backed companies, subsidiaries of Fortune 100 firms and publicly traded companies. His core strengths include operational management, strategic planning and corporate and business development, fundraising, and mergers and acquisitions.

Read More

Mark H. Breedlove, MBA

Mr. Breedlove is General Partner for the Breedlove Family Limited Partnership, a family investment partnership and acts as managing partner with specific responsibility for its direct investments in private companies. Since 2006 the partnership has been an angel investor in early stage life sciences companies with five current active interests. Mr. Breedlove has responsibilities as a board member for Cognition Therapeutics and sits on the board of one other life sciences company and one manufacturing company.

Read More

Susan Catalano, PhD

Dr. Catalano is the founder of Cognition Therapeutics and architect of its proprietary and unique biological discovery platform that is based on unbiased phenotypic screens in the target cell population of mature primary neurons. She is an expert in synaptic plasticity, Alzheimer’s disease and the biology of protein oligomers, the toxic shapes of protein that underlie many neurodegenerative diseases.

Read More

Aaron Fletcher, PhD

Dr. Fletcher has worked as an independent consultant for the biotech/healthcare equity industry for over 10 years. Dr. Fletcher has a strong understanding of commercial viability in the marketplace through his activities as a healthcare consultant to provide fundamental healthcare intelligence focused on the biotech and med-tech sub-sectors.

Read More

Robert Gailus, MBA

Mr. Gailus is a former member of the New York Angels and has been the Venture Advisor to OgdenCAP Asoociates LLC in New York City since 2006. His expertise is identifying early stage investment opportunities and working with companies on their strategic direction and focus, adding or strengthening their management skills and organizational processes, recruiting outside board members and ensuring that they have adequate capital to execute their business plan.

Read More

Kenneth Moch

Mr. Moch joined Cognition Therapeutics in October 2016 as President & CEO. He has broad expertise building, financing and leading private and public life science companies from start-up through commercialization, having previously served as President & CEO of four life science companies: Chimerix, Inc., BioMedical Enterprises, Alteon, Inc., and Biocyte Corporation, where he pioneered the storage and therapeutic use of cord blood stem cells and launched the first cord blood stem cell storage bank.

Read More

Stephen Sands, MBA

Mr. Sands joined the Cognition Therapeutics board in August 2017. Mr. Sands is the Vice Chairman of Investment Banking and Chairman of the Global Healthcare Group at Lazard. He has built a 25-year career providing strategic and financial advice to senior executives and boards of directors at leading healthcare and life sciences companies globally.

Read More

Irwin Scher, MD

Dr. Scher has a wealth of experience working with biotechnology and pharmaceutical companies. He is currently a member of the board of Intarcia Therapeutics Inc., a privately held biotechnology company. He is also a founder and chairman of the board of Opertech Inc. and has served as the Chief Executive Officer for Biosynexus.

Read More

Peggy Wallace

Ms. Wallace joined the Cognition Therapeutics board in January 2017. She is a managing partner at Golden Seeds, a venture capital firm dedicated to raising capital for women entrepreneurs and to encouraging both women and men to become active venture investors. She is a general partner of Golden Seeds Fund and Golden Seeds Fund 2, and works with companies and their board representatives to build a post-investment environment that fosters the growth of companies in the portfolio.

Read More

Michael Cahill, PhD

Dr. Cahill is currently lecturer in Biochemistry and Cell Biology at the School of Biomedical Sciences, Charles Sturt University, Wagga Wagga, NSW, Australia. He has been a Scientific Advisor for Cognition Therapeutics since 2013. His research interests revolve around the role of the protein PGRMC1 in cancer signaling and cellular metabolic regulation, stemming originally from earlier work he had done in the emerging field of proteomics.

Read More

John Cirrito, PhD​

Dr. Cirrito’s research has focused on understanding the metabolism of Abeta and its accumulation as toxic oligomers and plaques within the brain interstitial fluid (ISF). He has developed in vivo microdialysis techniques that enable him to specifically measure ISF ABeta within the brains of awake wild type and APP transgenic mice, providing kinetic information about how Abeta levels change over time under various settings such as aging, behavior, drug treatment, and genetic manipulation. One aspect of his current research is focused on postsynaptic signaling mechanisms that decrease ABeta generation.

Read More

Rolf Craven, MD

Dr. Craven research interests are primarily in signaling pathways associated with cancer progression, and his laboratory has developed multiple inhibitors to different pathways associated with tumor growth, invasion and metastasis. Most recently, he has focused on sigma-2/PGRMC1 and its role in cellular signaling by helping to process or transport signaling proteins as they are being synthesized.

Read More

Steven DeKosky, MD

Dr. DeKosky is an international leader in Alzheimer’s disease, renowned for his translational biomedical research leveraging scientific findings towards development of new treatments for patients. His clinical and translational research centers on understanding the genetics, neuropsychiatric symptoms, neuroimaging, and treatment and prevention of Alzheimer's Disease.

Read More

Alison Goate, MD

Dr. Goate started working on Alzheimer's disease genetics in 1987 as a postdoctoral fellow with Dr. John Hardy at Imperial College, London. Since then she has been part of many gene finding teams that have successfully identified disease causing variants for Alzheimer’s and frontotemporal dementia. Whilst working with Dr. Hardy she reported the first mutation to cause familial Alzheimer's disease. In 1992 she moved to Washington University where among her most significant findings was the identification of the presenilin1 mutation in the Colombian kindreds now being studied in the Alzheimer’s Prevention Initiative clinical trials.

Read More

Cynthia A. Lemere, PhD

Dr. Lemere is currently Associate Professor of neurology in the Ann Romney Center for Neurologic Diseases at Brigham & Women's Hospital and Harvard Medical School in Boston. Her interests include: the role of the immune system in Alzheimer's and therapeutic potential of immune proteins on clearance of amyloid-beta from the brain; better understanding of the progression of Alzheimer’s disease in Down syndrome; and the relationship of pyroglutamate amyloid-beta to Alzheimer’s disease and its value as a therapeutic target.

Read More

Harry LeVine, III, PhD

Dr. LeVine is a world leader in the biochemistry of Abeta protein and drug discovery efforts directed against this target. His current research focuses on biochemical and biophysical approaches to learn how toxic oligomeric forms of the Alzheimer’s Abeta peptide are generated and why they persist. His goals include a detailed mechanistic understanding of oligomer formation, cellular mechanisms for dealing with intracellular misfolded proteins, and the pharmacological manipulation of these toxic oligomers for therapy.

Read More

Robert Mach, PhD

Dr. Mach has over 25 years experience in the development of radiotracers for PET and SPECT. He is currently leading a multi-disciplinary research program aimed at developing PET radiotracers for imaging cell proliferation, dopamine receptor dysregulation in CNS disorders, mechanisms of cell death, oxidative stress, and cardiovascular disease. Some of this work has specifically been directed towards characterizing radiotracers for the sigma-2 receptor and PET tracers for imaging alpha-synuclein.

Read More

Robert C. Malenka, MD, PhD

Dr. Malenka is the Pritzker Professor of Psychiatry and Behavioral Sciences and Director of the Pritzker Laboratory at the Stanford University School of Medicine. He is a world leader in the molecular mechanisms of how neurons communicate with one another and how this communication is modified during learning and by experience. He is an elected member of the Institute of Medicine of the National Academy of Sciences and an elected fellow of the American Academy of Arts and Sciences.

Read More

Lon Schneider, MD​

Dr. Schneider is professor of psychiatry, neurology, and gerontology at the Keck School of Medicine and Leonard Davis School of Gerontology of the University of Southern California. He directs the USC State of California Alzheimer’s Disease Center and the clinical core of the USC National Institute on Aging Alzheimer’s Disease Research Center. He served as a senior scientific advisor at the NIMH, on the American Psychiatric Association Committee for Practice Guidelines in Alzheimer’s and Other Dementia, the World Federation of Societies of Biological Psychiatry Task Force on Dementia.

Read More

Dominic Walsh, MD

Dr. Walsh has been at the forefront of research on the role of soluble Abeta oligomers in Alzheimer's disease for many years with the ultimate goal to facilitate the development of rationally designed drugs that will slow or halt disease. Dr. Walsh has provided expert analysis of Alzheimer disease research on TV and radio and has worked tirelessly to highlight the need for more investment in clinical and research services.

Read More